203436-13-9

Basic information

• Product Name: 9H-Purin-6-aMine, 2-chloro-N-[(4-Methoxyphenyl)Methyl]-9-(1-Methylethyl)-
• Synonyms: 9H-Purin-6-aMine, 2-chloro-N-[(4-Methoxyphenyl)Methyl]-9-(1-Methylethyl)-;2-Chloro-9-isopropyl-N-(4-methoxybenzyl)-9H-purin-6-amine
• CAS NO: 203436-13-9
• Molecular Formula: C₁₆H₁₈ClN₅O
• Molecular Weight: 331.80002
• Mol File: 203436-13-9.mol

Chemical Properties

• Boiling Point: 483.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.39±0.10(Predicted)
• CAS DataBase Reference: 9H-Purin-6-aMine, 2-chloro-N-[(4-Methoxyphenyl)Methyl]-9-(1-Methylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 9H-Purin-6-aMine, 2-chloro-N-[(4-Methoxyphenyl)Methyl]-9-(1-Methylethyl)-(203436-13-9)
• EPA Substance Registry System: 9H-Purin-6-aMine, 2-chloro-N-[(4-Methoxyphenyl)Methyl]-9-(1-Methylethyl)-(203436-13-9)

Safety Data

• Hazardous Substances Data: 203436-13-9(Hazardous Substances Data)

Upstream product

• 2393-23-9 4-methoxy-benzylamine 
• 203436-45-7 2,6-dichloro-9-isopropyl-9H-purine 
• 5451-40-1 2,6-dichloro-7H-purine 
• 203436-09-3 2-chloro-6-(4-methoxybenzylamino) purine 
• 75-30-9 2-iodo-propane 
• 203436-09-3 2-chloro-N-(4-methoxybenzyl)-9H-purin-6-amine 
• 5451-40-1 2,6 dichloropurine 

Downstream Products

• 1100641-76-6 C₂₀H₂₇N₇O 
• 1061331-95-0 trans-[PtCl₂(2-chloro-6-((4-methoxybenzyl)amino)-9-isopropylpurine)2] 
• 1061331-95-0 cis-[PtCl₂(2-chloro-6-((4-methoxybenzyl)amino)-9-isopropylpurine)2] 

Relevant articles and documents

Synthesis and pharmacophore modelling of 2,6,9-trisubstituted purine derivatives and their potential role as apoptosis-inducing agents in cancer cell lines

Twelve compounds were obtained by a three step synthetic procedure using microwave irradiation in a pivotal step. All compounds were evaluated in vitro to determine their potential effect on cell toxicity by the MTT method and flow cytometry analysis on four cancer cells lines and Vero cells. Three out of twelve compounds were found to be promising agents compared to a known and effective anticancer drug, etoposide, in three out of four cancer cell lines assayed with considerable selectivity. Preliminary flow cytometry data suggests that compounds mentioned above induce apoptosis on these cells. The main structural requirements for their activity for each cancer cell line were characterized with a preliminary pharmacophore model, which identified aromatic centers, hydrogen acceptor/donor center and a hydrophobic area. These features were consistent with the cytotoxic activity of the assayed compounds.

Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases

Several inhibitors of cyclin-dependent kinases (CDKs), including the 2,6,9-trisubstituted purine derivative roscovitine, are currently being evaluated in clinical trials as potential anticancer drugs. Here, we describe a new series of roscovitine derivatives that show increased potency in vitro. The series was tested for cytotoxicity against six cancer cell lines and for inhibition of CDKs. For series bearing 2-(hydroxyalkylamino) moiety, cytotoxic potency strongly correlated with anti-CDK2 activity. Importantly, structural changes that increase biochemical and anticancer activities of these compounds also increase elimination half-life. The most potent compounds were investigated further to assess their ability to influence cell cycle progression, p53-regulated transcription and apoptosis. All the observed biological effects were consistent with inhibition of CDKs involved in the regulation of cell cycle and transcription.

Purine inhibitors of cyclin dependent kinase 2

A 2,6,9-trisubstituted purine composition having the following formula: STR1 where X is a amino, oxo, thio, of sulfone moiety, R1 is a lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cyclo

Synthesis and activity of 2,6,9-trisubstituted purines

The preparation of a series of 2,6,9-trisubstituted purines and the structure-activity data for the inhibition of cyclin dependent kinase, CDK2 are presented.